Australia Approves 90% Accurate Blood Test for Alzheimer's

A simple blood test could soon catch Alzheimer's disease up to 30 years before memory loss begins, giving hundreds of thousands of Australians hope for early treatment and more time with loved ones.

Australia's Therapeutic Goods Administration just approved the pTau217 blood plasma test, which detects a key biomarker linked to Alzheimer's with around 90% accuracy. Results arrive in just 18 minutes at Sydney's new Asia-Pacific Centre of Excellence for Alzheimer's Diagnosis.

The timing couldn't be better. About 446,500 Australians currently live with dementia, and Alzheimer's accounts for two-thirds of those cases. Traditional diagnosis requires invasive lumbar punctures or expensive PET scans that many people delay or skip entirely.

Dr. Emma Devenney, the neurologist overseeing the new testing center, believes this changes everything. "I think it's going to transform Alzheimer's disease and eventually dementia," she said, explaining the field is moving toward "early diagnosis, early treatments; and dementia and Alzheimer's disease will become treatable."

The science behind the breakthrough is remarkable. Alzheimer's-related changes start in the brain 20 to 30 years before someone forgets a grandchild's name or gets lost driving home. This test can spot those changes when interventions might actually stop the disease from progressing.

Dr. Anand Vairavan from Roche Diagnostics emphasized what early detection really means for families. "Earlier diagnosis really gives people something incredibly valuable, which is time," he said. "Time to understand what's happening, time to plan for the future, and to access care and treatment sooner."

The Ripple Effect

Beyond individual patients, this approval could reshape how healthcare systems approach dementia worldwide. Australia's testing center will serve the entire Asia-Pacific region, meaning millions of people across multiple countries gain access to this technology.

NeuRA is already developing national guidelines for the test, with clinical referrals expected within six to nine months. That means by early 2027, Australian doctors could routinely order this blood test just like they check cholesterol or blood sugar levels.

Professor Scott Ayton from the Florey Institute urged patience as the system scales up. "As a researcher I'm really excited by this, but I'm also cautious about everyone in the community knocking on their doctor's door to say, 'I want this blood test'," he said. The infrastructure for widespread screening will take time to build.

The real promise lies in pairing early detection with emerging treatments. Researchers hope catching Alzheimer's decades early will allow patients to access new disease-modifying medications when they can still make a difference, potentially preventing the devastating progression that robs people of their memories and independence.

For the nearly half-million Australians living with dementia and the families who support them, this approval represents something precious: hope backed by science.

#